The interferon gene signature is increased in early treatment-naïve rheumatoid arthritis and predicts a poorer response to initial therapy

The interferon gene signature in early, disease modifying drug naïve rheumatoid arthritis predicts clinical outcomes at 6 months after therapy initiation. We suggest type 1 interferons may be a future therapeutic target in early RA.

http://ift.tt/2xTMg2S